Format

Send to

Choose Destination
Semin Respir Infect. 1993 Sep;8(3):225-32.

Prevention of cytomegalovirus disease.

Author information

1
Department of Internal Medicine, Washington University School of Medicine, St Louis, MO.

Abstract

Cytomegalovirus (CMV) disease is a significant cause of morbidity in allogeneic bone-marrow and solid-organ transplant recipients. Because of this, a number of strategies to prevent this disease have been attempted, many of which were investigated before the approval of agents that are effective in treatment. However, in bone-marrow transplantation, treatment of established disease, particularly CMV pneumonitis, carries a high mortality rate despite appropriate management. A patient-survival benefit has been shown for preemptive therapy with ganciclovir initiated on the basis of a positive CMV surveillance culture from any site before post-transplant day 100, and this should be considered the current standard of care. Among solid-organ transplant recipients, no clear standard of care has emerged, and for most patients, the basic question of whether prophylaxis is more beneficial than treatment of symptomatic infection goes unanswered.

PMID:
8016483
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center